References
- Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272–281.
- Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519–1531.
- DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
- Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463–471.
- DiNardo CD, Stein AS, Stein EM, et al. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia. J Clin Oncol. 2021;39(1):57–65.
- Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
- Bewersdorf JP, Patel KK, Goshua G, et al. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood. 2022;139(11):1766–1770.
- Zeidan AM, Stahl M, Hu X, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131(7):818–821.
- Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
- Centers for Medicare & Medicaid Services. ASP drug pricing files April 2022 update. Vol. 2022; 2022 [cited 2022 May 27]. Available from: https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022-asp-drug-pricing-files
- Lexicomp. Ivosidenib (lexi-drugs). [cited 2022 Jun 3]. Available from: https://online.lexi.com/lco/action/home
- Polite BN, Ward JC, Cox JV, et al. Payment for oncolytics in the United States: a history of buy and bill and proposals for reform. J Oncol Pract. 2014;10(6):357–362.
- Abraham P, Gholmie J, Rodriguez-Monguio R, et al. PHP54 - a comparison of the medicare average sales price and the average wholesaler price. Value Health. 2014;17(3):A19.
- Department of Health and Human Services Office of Inspector General. Medicaid drug price comparison: average sales price to average wholesale price. [cited 2021 Apr 13]. Available from: https://oig.hhs.gov/oei/reports/oei-03-05-00200.pdf
- Bewersdorf JP, Patel K, Huntington SF, et al. Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. Blood Adv. 2021;5(22):4686–4690.
- Centers for Medicare & Medicaid Services. Physician fee schedule. [cited 2022 May 27]. Available from: https://www.cms.gov/medicare/physician-fee-schedule/search/license-agreement?destination=/medicare/physician-fee-schedule/search%3FY%3d0%26T%3d4%26HT%3d0%26CT%3d0%26H1%3d96401%26M%3d5
- Oliva EN, Kambhampati S, Oriol A, et al. CC-486 reduces hospitalization and associated estimated costs in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy: results from the QUAZAR AML-001 maintenance trial. Blood. 2020;136(Suppl 1):14–15.
- Dinardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407.
- Sarkozy C, Gardin C, Gachard N, et al. Outcome of older patients with acute myeloid leukemia in first relapse. Am J Hematol. 2013;88(9):758–764.
- Hagiwara M, Sharma A, Chung KC, et al. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia. J Med Econ. 2018;21(11):1119–1130.
- Bell JA, Galaznik A, Farrelly E, et al. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018;71:27–33.
- Chastek B, Harley C, Kallich J, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6):75s–80s.
- Coyle D, Villeneuve PJA. Economic evaluation of azacitidine in elderly patients with acute myeloid leukemia with high blast counts. Pharmacoecon Open. 2020;4(2):297–305.
- Bureau of Economic Analysis USDoC. Table 2.5.4. Price indexes for personal consumption expenditures by function. [cited 2022 May 27]. Available from: https://apps.bea.gov/iTable/iTable.cfm?reqid=19&step=2#reqid=19&step=2&isuri=1&1921=survey
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
- DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
- Pollyea DA, Pratz KW, Wei AH, et al. Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022;28:OF1–OF8.
- Patel KK, Zeidan AM, Shallis RM, et al. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 2021;5(4):994–1002.